This study characterized cancer stem cells (CSCs) 
INTRODUCTION
Cancer stem cells (CSCs) are the source of many solid tumor types (Al-Hajj et al., 2003; Singh et al., 2004; Collins et al., 2005; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Li et al., 2007) , including hepatocellular carcinoma (HCC). HCC is the fifth most common cancer in the world and comprises more than 90% of human liver cancers. The incidence of HCC is increasing due to increased rates of hepatitis B and C viral infection (Llovet et al., 2003; McMahon, 2005; El-Serag, 2004) . Hepatic resection and liver transplantation are the two main treatment modalities for HCC, and the 5 year survival rate correlates with tumor staging at the time of diagnosis (Mazzaferro et al., 1996; Llovet et al., 1999; Arii et al., 2000) . The majority of HCC patients present with an advanced stage of cancer for which chemotherapy and radiotherapy have limited efficacy (Groupe d'Etude et de Traitement du Carcinome Hé patocellulaire, 1995; Lo et al., 2002) . Hence, understanding the mechanism underlying hepatocarcinogenesis is essential for the management of liver malignancy.
CSCs have been characterized in solid tumors using a variety of stem cell markers, including CD133 (Tang et al., 2007) . Although CD133 can identify CSCs in cell line-induced HCC (Suetsugu et al., 2006; Yin et al., 2007; Ma et al., 2007) , the CD133 + cells isolated from human tumor specimens are not well characterized. Furthermore, the CD133 À cells also have the capacity to generate tumor nodules in immunodeficient mice, although at a higher cell number . Previously, we showed that CD133 is a marker of circulating endothelial progenitor cells (EPCs) in HCC patients (Ho et al., 2006) . Together, the above evidence suggests that CD133 is not sufficiently sensitive or specific to be a marker of CSCs in liver malignancy.
CD90 (Thy-1) is a 25-37 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed mainly in leukocytes and is involved in cell-cell and cell-matrix interactions (Rege and Hagood, 2006) . CD90 is also expressed by bone marrow-derived mesenchymal stem cells (Dennis et al., 2007) and hepatic stem/progenitor cells (HSPCs) (Lá zaro et al., 2003; Herrera et al., 2006; Dan et al., 2006) . In addition, CD90 expression was identified in murine breast CSCs (Cho et al., 2007) and primarily cultured CD133 + glioblastoma CSCs (Liu et al., 2006) . Based on the above findings, CD90 was used in the present study to identify potential hepatic CSCs from
SIGNIFICANCE
This study reveals that CD90 is a potential marker of liver CSCs, and the concomitantly expressed CD44 modulates the biological activity of the CD90 + CSCs. The presence of local and circulating CSCs implies the aggressive phenotype of liver malignancy, in which the CD90 HCC cell lines, tumor specimens, and blood samples of liver cancer patients.
RESULTS

Tumorigenic Capacity of CD90
+ Cells Isolated from HCC Cell Lines Six human HCC cell lines, specifically HepG2, Hep3B, PLC, Huh7, MHCC97L, and MHCC97H, and one immortalized nontumorigenic normal human hepatocyte cell line, MIHA , were used to screen for the expression of stem cell markers by flow cytometry. The tumorigenic potential of the 6 HCC cell lines ranges from low in HepG2 to high in MHCC97H. In the present study, tumorigenicity is defined as the capacity of a certain cell number, following serial dilution, to form tumor nodules in immunodeficient mice within a certain time interval (Table 1) . Three time points were used for the assessment of tumorigenicity of cell lines and the cells isolated from human tumor specimens and blood samples. Differentially expressed stem cell markers were detected in the HCC cell lines, among which only the expression of CD90 correlated positively with tumorigenicity and metastatic properties of cell lines (see Table S1 available with this article online).
The CD90 + cells were isolated from HCC cell lines using magnetic microbeads and injected subcutaneously into BALB/c nude mice using the CD90 À cells as a control. Tumor nodules from the CD90 + cells isolated from both MHCC97L and MHCC97H cell lines appeared after 3 months from 500 inoculated cells. When the cell number was increased to 1,000, the CD90 + cells from 4 out of 6 HCC cell lines (PLC, Huh7, MHCC97L, and MHCC97H) generated tumor nodules in nude mice at 2 months. In cell line with low tumorigenic capacity, HepG2, a higher number of CD90 + cells (5,000 cells at 3 months) or a longer observation time (4 months with 1,000 cells) was needed for tumor development (Table 1) . In contrast, the CD90 À cells from all cell lines tested did not induce tumor formation in nude mice, even 4 months after injecting 1 3 10 4 cells. MHCC97L cell line was chosen to illustrate histological characteristics of tumor xenografts MIHA is an immortalized nontumorigenic normal human hepatocyte cell line. ND, not determined. The number of the CD90 + cells was expressed as mean percentage ± SD (representative of three independent experiments). Tumorigenicity by cell number was defined as the lowest number of total tumor cells that were capable of inducing tumor formation at 2 months after cell injection, whereas tumorigenicity by time was defined as the shortest time interval that was required for 1 3 10 6 total tumor cells to develop tumors. The sorted CD90 + and CD90 À cells from different cell lines were injected subcutaneously into two different sites of a same nude mouse. Animals were sacrificed when tumor nodules were identified in nude mice, otherwise the mice were monitored continuously until the second or third time point.
induced by total tumor cells (1 3 10 6 ) and the isolated CD90 + cells (1 3 10 4 ). Hematoxylin-eosin (H&E) staining identified similar histological features in tumor xenografts generated by the above two types of cells. Immunohistochemical staining (IHC) analysis showed scattered and clustered distribution of the CD90 + cells with both membrane and cytoplasm localization of CD90 expression ( Figure 1A ). Serial transplantation was performed by subcutaneous injection of the CD90 + cells isolated from tumor xenografts into a second and subsequently third batch of nude mice. Tumor nodules comparable to those isolated from HCC cell lines appeared after 2 months from the CD90 + cells isolated from tumor xenografts (Table S2A) . Flow cytometry showed a similar level of the CD90 + cells in the first and second generation of tumor xenografts and HCC cell lines, suggesting a re-establishment of cellular hierarchy in tumors (Table S2B) .
Further multimarker analyses revealed that the majority of CD90 + cells in HCC cell lines also expressed CD44 (Figure 1Ba ), a marker for HSPCs and an adhesion molecule that modulates tumor cell invasion and migration (Lara-Pezzi et al., 2001 (Figure 2A ). The effect of CD44 blockade on tumor formation was further investigated in vivo. The CD90 + cells from MHCC97L cell line were injected subcutaneously or directly into the liver of nude mice to generate local and metastatic tumor models, respectively. Different doses (5 mg/kg or 10 mg/kg, intravenous injection twice per week) of anti-CD44 antibody were administered Cancer Cell 
Validation of Tumorigenic Properties of the CD45
À
CD90
+ Cells Isolated from Human Tumor Specimens and Blood Samples Based on the findings in HCC cell lines, CD90 was used as a marker to characterize CSCs in human tumor specimens, including 2 dysplastic nodules, 25 HCCs, and 3 intrahepatic cholangiocarcinomas (Cholangio Ca). The clinical data of liver cancer patients and controls is summarized in Table S3A . Since CD90 is also expressed by some lymphocytes, a combination of CD45 À CD90 + was used to define nonlymphatic CD90 + cells in tumor tissues. Flow cytometry revealed the presence of a small number (0%-0.03%) of CD45 À CD90 + cells in normal, cirrhotic, and parallel nontumorous liver specimens. By comparison, the CD45 À CD90 + cells (0.03%-6.2%) were detected in all the tumor specimens (Table S3b) . Our findings are consistent with the reports of the CD90 + cells at 0.01% in the normal adult liver (Nava et al., 2005) , and higher levels in neoplastic tissues (Ceafalan et al., 2005) . Multimarker analyses demonstrated that a proportion of CD45 (Table S3B) , ESA, CXCR4, CD24, and KDR (Table  S4) . Interestingly, small numbers of CD45 À CD90 + cells were also detected in one of the two dysplastic nodules, a precancerous stage of HCC (Table S3b) . Our preliminary data revealed that >80% viable cells were required for the in vivo tumorigenicity assay. Among the 28 tumor specimens collected, the cells isolated from 13 tumor specimens showed >80% cell viability, and these cells were then used for the in vivo tumorigenicity assay. After removal of dead cells, the CD45 À CD90 + cells were isolated from individual tumor specimens using magnetic microbeads and injected orthotopically into the liver of individual severe-combined immunodeficient (SCID)/Beige mice. The isolated CD45 À cells (total tumor cell control) from all the 13 tumor specimens formed tumor nodules in immunodeficient mice with the cell number of 1 3 10 6 at 4 months after cell injection. At 3 months, the CD45 Figure 4A and Table S3B ).
In the next series of experiments, the CD45 À CD90 + cells were isolated from blood samples from 10 HCC patients and injected into the liver of SCID/Beige mice individually. At 4 months, the CD45 À cells (bulk control; cell number = 1 3 10 6 ) from all the blood samples formed tumor nodules in immunodeficient mice. At the same observation time, tumor formation was also induced by 5,000 CD45 À CD90 + cells isolated from blood sample of 5 HCC patients. When the cell number was increased to 10,000, circulating CD45 À CD90 + cells from all HCC patients developed tumor nodules in the mice (Table 3 ). The generated tumor nodules displayed similar histological features to the primary tumors of liver cancer patients, and IHC revealed strong expression of human hepatocyte antigen in tumor xenografts. IF 
+ cells, compared with those sorted from normal, cirrhotic, and nontumorous liver tissues ( Figure 5A ). The CD45 À CD90 + cells isolated from different groups expressed a comparable level of Notch1 ( Figure 5B ). In contrast, the expression of AFP, VIL2, MMP1, and JUNB mRNA was significantly higher in the CD45 À CD90 À cells sorted from tumor tissues, compared with those isolated from control tissues ( Figure 5C ). Finally, the expression of another group of genes, including Wnt3a, signal transducers and activators of transcription 3 (stat3), and hypoxia inducible factor-1a (HIF-1a), was augmented in the CD45 À CD90 + cells isolated from cirrhotic, nontumorous and tumor tissues, prominently from cirrhotic and nontumorous livers, compared with those from normal liver tissues ( Figure 5D ).
In the circulation, the CD45 
+ cells than those in tumor tissues ( Figure 5 ).
DISCUSSION
The present study reveals that CD90 is a potential marker for liver CSCs. This is supported by the finding that the number of CD90 In our study, very low levels of CD45 À CD90 + cells are also present in normal and cirrhotic liver tissues, and this finding is consistent with others' findings (Fiegel et al., 2003; Isabel et al., 2006; Corcelle et al., 2006) . Therefore, an investigation of the differences between the CD45 À CD90 + cells isolated from tumor specimens or blood samples of liver cancer patients and those from normal or cirrhotic liver tissues may provide important clues to understand the mechanism underlying hepatocarcinogenesis. By qRT-PCR using specific primers, we have detected the augmentation of Oct4 and Bmi1, which modulate stem cell self-renewal and multipotency, in tumor tissue and circulating CD45 À CD90 + cells from liver cancer patients, thereby providing evidence of the stem cell nature of these cells and their potential role in hepatocarcinogenesis (Campbell et al., 2007; Bruggeman et al., 2007) . A comparable level of Notch1 expressed by both normal hepatic and tumor tissue CD45 À CD90 + cells indicates their similarity as stem cells (Chiba, 2006) , signifying that this gene might not play a prominent role in hepatocarcinogenesis. The enhanced expression of CD44 in tumor specimens, and a greater enhancement in circulating CD45 
CD90
À cells implies a role of these genes in the differentiation of CSCs into adult phenotypes (Curto and McClatchey, 2004; Seiki, 2003; Jochum et al., 2001) . Lastly, the expression of another group of genes, Wnt3a, Stat3, and HIF-1a, was upregulated in the CD45 À CD90 + cells isolated from cirrhotic livers, nontumorous and tumor specimens, and blood samples of liver cancer patients. This finding, and the observation that upregulation was most prominent in cirrhotic and nontumorous livers, implies a potential role of these genes in linking chronic injury to hepatocarcinogenesis Kim et al., 2007; Paul et al., 2004; Yang et al., 2004a) .
Using an antibody specifically targeting murine CD90, we detected an increasing proportion of murine CD90
+ cells in secondary and tertiary tumor xenografts (data not shown). This result Animals were sacrificed when tumor nodules were identified in the mouse liver at the indicated time points by laparotomy; otherwise, the mice were monitored continuously until the second or third time point. Tumorigenic capacity was defined when tumor nodules were identified in either one of the two mice with cell injection.
suggests the formation of cell-cell fusions of human and murine cells during the growth of human tumor in immunodeficient mice. However, IHC studies using an antibody specifically targeting human hepatocyte antigen demonstrated that more than 90% of cells in tumor xenografts were human origin. Flow cytometry using anti-human and anti-murine CD90 antibodies revealed that <0.5% of the total cell population was double positive. These results indicate that the proportion of cell-cell fusion in tumor xenografts is low. We hypothesize that the murine CD90 + cells favor the survival, self-renewal, differentiation, and metastasis of human CSCs mainly through participation in the establishment of a microenvironment (Gilbertson and Rich, 2007; Karnoub et al., 2007) , rather than direct integration with human cells. The present study has shown the presence of local and circulating tumorigenic CD45 À CD90 + , and an aggressive subpopulation of CD90 + CD44 + CSCs in human liver cancer. Due to the small number of cases and short follow-up period, detailed statistical analyses could not be performed to evaluate the correlation between the number of CSCs and clinico-pathological features of liver cancer patients. The universal presence of the CD45 and MHCC97H (HCC cell lines with low to high metastatic properties, respectively [Tang et al., 2004] ), were maintained as monolayer cultures in high glucose Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin (Life Technologies, Carlsbad, CA) at 37 C in a humidified atmosphere of 5% CO 2 in air.
Patients and Sample Collection
Two patients with dysplastic nodules (2/2 were liver transplantation recipients) and 36 patients with liver tumors who had undergone laparotomy (24/36 had curative hepatic resection, 4/36 received liver transplantation, and 8/36 had liver biopsy) were recruited in this study. Pathological diagnosis was made according to the histology of tumor specimens or biopsy and examined by experienced pathologists. Nineteen patients with cirrhosis (10/19 received liver transplantation) and 19 normal subjects (10/19 were liver donors) were used as controls. The diagnosis of cirrhosis was made according to histological findings in liver explants or CT/MRI scan results. The majority of patients with HCC (28/36) and cirrhosis (15/19) were positive for serum hepatitis B surface antigen (HBsAg). All tissue and blood samples were obtained from consenting patients and approved by the Institutional Review Board of the University of Hong Kong. The clinical data for the above patients and controls are summarized in Table S3 . Tumor, parallel nontumorous, cirrhotic, and normal liver tissues were harvested at the time of operation and placed into DMEM medium. The procedure of cell isolation from liver tissues was performed as previously described (Yang et al., 2004b) with some modifications. In brief, after digestion with type IV collagenase (100 units/ml) (Sigma-Aldrich, St. Louis, MO) at 37 C for 15 min, tissues were minced and cell suspension was passed through a 40 mM nylon mesh. After lysis of red blood cells, cells were counted and subjected to flow cytometry analysis or cell sorting. Before the operation, 10 ml of EDTA blood were collected from patients and controls. Mononuclear cells were isolated from the EDTA blood using FicollPaque PLUS (Amersham Bioscience, Buckinghamshire, England) density gradient centrifugation before proceeding to flow cytometry analysis or cell sorting.
Flow Cytometry
The isolated cells from HCC cell lines, tissue, and blood samples were labeled with the following anti-human antibodies: FITC-ESA, FITC-CD44, PE-CD15, PE-CD24, PE-CD30, PE-CD32, PE-CD33, PE-CD38, PE-CD56, PE-CD59, PE-CK19, PE-CD117, PE-KDR, purified or PE-CD90, APC-CD45, APC-CD34 (BD Biosciences PharMingen, San Diego, CA), PE-Cy5-CD44, PE-Cy5-CXCR4 (eBioscience, San Diego, CA), and PE-CD133 (Miltenyi Biotech Inc, Bergisch Gladbach, Germany). Labeled cells were detected using a FACSCalibur (Tian et al., 1999) . Hence, the CD90 + and CD90 À cells isolated from different HCC cell lines were injected subcutaneously into two sides of the same nude mouse, respectively, for controlled visualization and comparison. To favor cell growth, the cells isolated from human tumor tissues and blood samples were injected orthotopically into the left lobe of the liver of SCID/Beige mice as previously described (Yang et al., 2005 MHCC97L cell line were injected orthotopically into the liver of different BALB/c nude mice. A total of 1 3 10 6 tumor cells were injected into immunodeficient mice to serve as a control of cell viability. Animals were sacrificed at the indicated time intervals when tumor nodules were identified on the body surface of nude mice or in the liver of SCID/Beige mice by laparotomy. If tumors were not identified, the abdominal incision was closed by sutures, and the mice were monitored until the second or third time point. In the tumor metastasis model, animals were sacrificed at 4 months after cell injection to investigate the formation of liver and lung lesions.
Blockade of CD44 Activity In Vitro and In Vivo
For in vitro experiments, the CD90 + and CD90 À cells isolated from HCC cell lines were treated for 24 hr with different doses (0, 1.5, 3, 6, 12, or 24 mg/ml) of anti-human CD44 antibody (International Blood Group Reference Laboratory, Bristol, England). The cells were then labeled with Annexin-V and Propidium iodide (PI) (BD Biosciences PharMingen) and detected in a FACSCalibur (Becton Dickinson Immunocytometry Systems). For in vivo experiments, 5,000 or 10,000 CD90 + cells were isolated from HCC cell line and injected subcutaneously into BALB/c nude mice. In the lung metastasis model, the CD90 + and CD90 À cells were isolated from MHCC97L cell line and injected into the left lobe of the liver of BALB/c nude mice, respectively. At the time of cell inoculation, anti-human CD44 antibody was administered intravenously (5 mg/kg or 10 mg/kg twice per week). The mice were monitored continuously for signs of subcutaneous tumor formation, or sacrificed at 4 months to investigate tumor formation in the liver and lung.
Histological Studies
The embedded tissues were cut into 5 mm-thick sections for histological analyses by H&E staining, IHC to detect CD90 and human hepatocytes (Dako, Glostrup, Denmark), and IF to examine CD44 and CD90 expression. The anti-human hepatocyte antibody recognizes human liver tumors by IHC (Minervini et al., 1997) . Our preliminary investigations showed that the anti-human hepatocyte antibody did not crossreact with murine antigen. Sections were incubated sequentially with primary and secondary antibodies for 1 hr at room temperature. Counter-staining of the nucleus was performed using hematoxylin and DAPI for IHC and IF, respectively.
Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction
Total RNA was extracted from the isolated CD45 À CD90 + and CD45 À CD90 À cells from tissue or blood using the RNeasy RNA Mini Kit (QIAGEN Inc., Valencia, CA). RNA was resuspended in 30 ml RNase-free water. First strand cDNA was synthesized by using ImProm-II reverse transcriptase (Promega, Madison, WI). Real-time qPCR was performed using the first strand cDNA, 10 mM forward and reverse primers, and the SYBR Green PCR master mix. The primer sequences and PCR conditions are summarized in Table S7 . The reactions were performed using the ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA). Fluorescence signals were analyzed using SDS 1.9.1 software (Applied Biosystems). Expression levels were calculated as the relative expression ratio compared to b-actin. 
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The Supplemental Data include seven supplemental tables and can be found with this article online at http://www.cancercell.org/cgi/content/full/13/2/153/ DC1/.
